Sec Form 4 Filing - JOHNSON & JOHNSON @ CVRx, Inc. - 2024-02-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person JOHNSON & JOHNSON 2. Issuer Name and Ticker or Trading Symbol CVRx, Inc. [ CVRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE JOHNSON & JOHNSON PLAZA 3. Date of Earliest Transaction (MM/DD/YY) 02/16/2024 (Street) NEW BRUNSWICK, NJ08933 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/16/2024 X 607,725 A $ 0.158 4,103,300 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/16/2024 S( 2 ) 3,725 D $ 25.81 4,099,575 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 158 A $ 0.237 4,099,733 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 189 A $ 0.237 4,099,922 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 165 A $ 0.237 4,100,087 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 118 A $ 0.237 4,100,205 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 71 A $ 0.237 4,100,276 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 23 A $ 0.237 4,100,299 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 85 A $ 0.237 4,100,384 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 758 A $ 0.237 4,101,142 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 489 A $ 0.237 4,101,631 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 584 A $ 0.237 4,102,215 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 300 A $ 0.237 4,102,515 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 442 A $ 1.186 4,102,957 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 142 A $ 1.186 4,103,099 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 252 A $ 3.955 4,103,351 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Common Stock 02/29/2024 M 79 A $ 5.141 4,103,430 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant to Purchase Common Stock $ 0.158 02/16/2024 X 607,225 ( 3 ) ( 3 ) Common Stock 607,225 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) ( 4 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 158 ( 5 ) 11/18/2024 Common Stock 158 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 189 ( 5 ) 08/06/2025 Common Stock 189 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 165 ( 5 ) 08/06/2025 Common Stock 165 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 118 ( 5 ) 08/06/2025 Common Stock 118 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 71 ( 5 ) 08/06/2025 Common Stock 71 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 23 ( 5 ) 08/06/2025 Common Stock 23 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 85 ( 5 ) 11/09/2025 Common Stock 85 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 758 ( 5 ) 02/01/2027 Common Stock 758 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 489 ( 5 ) 02/01/2027 Common Stock 489 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 584 ( 5 ) 02/15/2028 Common Stock 584 $ 0 0 ( 6 ) I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 0.237 02/29/2024 M 300 ( 5 ) 02/15/2028 Common Stock 300 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 1.186 02/29/2024 M 442 ( 5 ) 11/28/2028 Common Stock 442 $ 0 0 ( 7 ) I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 1.186 02/29/2024 M 142 ( 5 ) 11/28/2028 Common Stock 142 $ 0 0 I By Johnson & Johnson Innovation - JJDC, Inc ( 1 ) Stock Option (Right to Buy) $ 3.955 02/29/2024 M 252 ( 5 ) 12/05/2029 Common Stock 252 $ 0 0 ( 8 ) I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 ) Stock Option (Right to Buy) $ 5.141 02/29/2024 M 79 ( 5 ) 01/04/2031 Common Stock 79 $ 0 0 ( 9 ) I By Johnson & Johnson Innovation - JJDC, Inc. ( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ08933 X Johnson & Johnson Innovation - JJDC, Inc. 410 GEORGE STREET NEW BRUNSWICK, NJ08901 X Signatures Johnson & Johnson By: /s/ Marc Larkins, Secretary 03/06/2024 Signature of Reporting Person Date Johnson & Johnson Innovation - JJDC, Inc. By: /s/ Jill McManus, Assistant Treasurer 03/06/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. ( 2 )On February 16, 2024, JJDC exercised the Warrant to purchase 607,725 shares of Common Stock and paid the exercise price (adjusted per the net exercise terms of the Warrant) on a cashless basis, resulting in the withholding of 3,725 of the Warrant shares to pay the exercise price and issuance to JJDC of the remaining 604,000 shares. ( 3 )The Warrant became exercisable for Common Stock upon the closing of the Issuer's initial public offering and was to expire on the earlier of (i) an acquisition or asset transfer involving the Issuer or (ii) 180 days after receipt of the data from the post-market stage of the Issuer's BeAT-HF pivotal trial. ( 4 )The Warrant was transferred to JJDC from Biosense Webster, Inc., also a wholly-owned subsidiary of Johnson & Johnson, on February 14, 2024. ( 5 )Fully vested. ( 6 )174 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. ( 7 )316 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. ( 8 )506 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. ( 9 )1,185 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.